Characteristics of the study cohort (N = 2169)
| Characteristic . | n (%) . |
|---|---|
| Number genotyped | |
| Recipients genotyped | 1930 (89) |
| Donors genotyped | 2025 (93) |
| Patient age at transplantation in years | |
| Median | 46 |
| Range | 0-75 |
| Diagnosis | |
| Acute leukemia | 907 (42) |
| Chronic myeloid leukemia | 487 (22) |
| Myelodysplastic syndromes or myeloproliferative neoplasms | 383 (18) |
| Chronic lymphocytic leukemia | 72 (3) |
| Malignant lymphoma or multiple myeloma | 320 (15) |
| Disease risk* | |
| Low | 445 (21) |
| Intermediate | 596 (27) |
| High | 1005 (46) |
| Not classified | 123 (6) |
| Donor-recipient gender combination | |
| Male to male | 659 (30) |
| Male to female | 538 (25) |
| Female to male | 476 (22) |
| Female to female | 494 (23) |
| Donor CMV serostatus | |
| Negative | 1168 (54) |
| Positive | 1000 (46) |
| Donor type | |
| Related, HLA-A, B, C, DRB1, DQB1-matched | 956 (44) |
| Related, HLA-A, B, C, DRB1, DQB1-mismatched | 63 (3) |
| Unrelated, HLA-A, B, C, DRB1, DQB1-matched | 746 (34) |
| Unrelated, HLA-A, B, C, DRB1, DQB1-mismatched | 404 (19) |
| Graft source | |
| Bone marrow | 1135 (52) |
| Mobilized blood cells | 1034 (48) |
| Conditioning regimen | |
| Myeloablative with <900 cGy total body irradiation | 788 (36) |
| Myeloablative with ≥900 cGy total body irradiation | 966 (45) |
| Nonmyeloablative | 415 (19) |
| Posttransplant immunosuppression | |
| Cyclosporine and methotrexate | 1141 (53) |
| Cyclosporine and mycophenolate mofetil | 378 (17) |
| Tacrolimus and methotrexate | 318 (15) |
| Other | 332 (15) |
| Characteristic . | n (%) . |
|---|---|
| Number genotyped | |
| Recipients genotyped | 1930 (89) |
| Donors genotyped | 2025 (93) |
| Patient age at transplantation in years | |
| Median | 46 |
| Range | 0-75 |
| Diagnosis | |
| Acute leukemia | 907 (42) |
| Chronic myeloid leukemia | 487 (22) |
| Myelodysplastic syndromes or myeloproliferative neoplasms | 383 (18) |
| Chronic lymphocytic leukemia | 72 (3) |
| Malignant lymphoma or multiple myeloma | 320 (15) |
| Disease risk* | |
| Low | 445 (21) |
| Intermediate | 596 (27) |
| High | 1005 (46) |
| Not classified | 123 (6) |
| Donor-recipient gender combination | |
| Male to male | 659 (30) |
| Male to female | 538 (25) |
| Female to male | 476 (22) |
| Female to female | 494 (23) |
| Donor CMV serostatus | |
| Negative | 1168 (54) |
| Positive | 1000 (46) |
| Donor type | |
| Related, HLA-A, B, C, DRB1, DQB1-matched | 956 (44) |
| Related, HLA-A, B, C, DRB1, DQB1-mismatched | 63 (3) |
| Unrelated, HLA-A, B, C, DRB1, DQB1-matched | 746 (34) |
| Unrelated, HLA-A, B, C, DRB1, DQB1-mismatched | 404 (19) |
| Graft source | |
| Bone marrow | 1135 (52) |
| Mobilized blood cells | 1034 (48) |
| Conditioning regimen | |
| Myeloablative with <900 cGy total body irradiation | 788 (36) |
| Myeloablative with ≥900 cGy total body irradiation | 966 (45) |
| Nonmyeloablative | 415 (19) |
| Posttransplant immunosuppression | |
| Cyclosporine and methotrexate | 1141 (53) |
| Cyclosporine and mycophenolate mofetil | 378 (17) |
| Tacrolimus and methotrexate | 318 (15) |
| Other | 332 (15) |
Low risk includes chronic myeloid leukemia in chronic phase or myelodysplastic syndrome-refractory anemia; intermediate risk includes acute leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma in remission; high risk includes all others.